Background
==========

Male breast cancer (MBC) is a rare disease, accounting for around 1% of all breast cancers \[[@b1-medscimonit-24-3425]\]. Although rare, its incidence has steadily increased \[[@b2-medscimonit-24-3425]\]. In 1991, an estimated 900 men in the United States were diagnosed with breast cancer; the number increased to 2550 men by 2018 \[[@b3-medscimonit-24-3425],[@b4-medscimonit-24-3425]\]. Although the mortality and survival rates of both male and female breast cancer patients have significantly improved, progress in men has been slower \[[@b5-medscimonit-24-3425]\]. Due to lack of prospective data and limited retrospective series, MBC usually has been treated according to recommendations for female breast cancer (FBC) \[[@b6-medscimonit-24-3425]\]. Although MBC shares some features with FBC, it significantly differs in prognostic factors, epidemiological factors, and biological behavior \[[@b7-medscimonit-24-3425],[@b8-medscimonit-24-3425]\]. For example, MBC tends to have higher rates of hormone receptor (HR) positivity compared to FBC \[[@b5-medscimonit-24-3425],[@b7-medscimonit-24-3425]\]. MBC is frequently positive for ERα (91--95%) and/or PR (80--81%) \[[@b5-medscimonit-24-3425],[@b9-medscimonit-24-3425],[@b10-medscimonit-24-3425]\]. Therefore, identifying prognostic factors in HR positive MBC can help to manage the majority of MBC cases.

Most cancer research focuses on biological aspects; the effect of social or psychological factors, such as marital status, on survival in cancer patients is much less studied. However, marriage has been shown to function as a positive social support with a survival benefit for cancer patients \[[@b11-medscimonit-24-3425]\]. The relationship between marital status and survival has been studied for some cancers, including hepatocellular cancer \[[@b12-medscimonit-24-3425]\], gastric cancer \[[@b13-medscimonit-24-3425]\], biliary tract cancer \[[@b14-medscimonit-24-3425]\], colorectal cancer \[[@b15-medscimonit-24-3425]\], prostate cancer \[[@b16-medscimonit-24-3425]\], pancreatic cancer \[[@b17-medscimonit-24-3425]\] and breast cancer \[[@b18-medscimonit-24-3425]\]. Marital status is an independent prognostic factor for survival, and married patients gain a significant survival benefit versus the unmarried, who are single, widowed, or separated/divorced patients \[[@b19-medscimonit-24-3425],[@b20-medscimonit-24-3425]\]. As for MBC, only 1 previous study reported that unmarried men were more likely to present with advanced disease at diagnosis and were at greater risk for poorer outcomes compared with married men \[[@b21-medscimonit-24-3425]\]. However, in that study, researchers did not control for confounding variables and the outcomes may have been subject to a selection bias. Additionally, they only took stage into consideration and could not discuss the effect of marriage on survival from other aspects, such as different ER/PR subtypes.

To our knowledge, no study has analyzed the influence of marital status on prognosis in HR positive MBC. Therefore, data from Surveillance, Epidemiology, and End Results (SEER) database was used to investigate the influence of marital status on survival and on potential subtypes in HR positive MBC.

Material and Methods
====================

Patient population and study design
-----------------------------------

We obtained permission to access SEER research-data files using the reference number 15983-Nov2016. Because no information from the SEER database requires informed patient consent, it is considered exempt from the ethical approval requirements of the institutional review board. The case listing in this retrospective cohort study was generated by SEER \*Stat version 8.3.5, which contained data from 18 population-based cancer registries (1973--2014) and covered approximately 28% of the United States population (*<http://seer.cancer.gov/>*). Male patients with first primary stages I--III and HR positive breast cancer diagnosed between 1990 and 2014 were selected from the SEER database. We selected the period starting from 1990 because HR status was introduced to SEER in 1990. We choose 3612 patients according to the following criteria: (a) at least 18 years old at diagnosis; (b) male; (c) diagnosed between 1990 and 2014; (d) known marital status; (e) known race; (f) known residence type; (g) pathologically confirmed breast cancer; (h) breast cancer as the first and only malignant cancer diagnosis; (i) known histology; (j) known grade; (k) American Joint Committee on Cancer stages I--III at diagnosis; (l) known tumor size; (m) known lymph node status; (n) HR positive (ER^+^ or PR^+^); (o) known HER2 status; (p) known surgical condition; (q) known radiotherapy condition; (r) active follow-up; (s) known survival months after diagnosis; and (t) known cause of death. We excluded patients for whom the aforementioned data was missing. Eligible patients were categorized by marital status, age at diagnosis, race, residence type, histology, tumor grade, pathologic T stage, pathologic N stage, ER status, PR status, HER2 status, surgery and radiotherapy. Marital status at diagnosis was the primary variable of interest, and classified as married or unmarried, the latter of which included patients who were single, divorced, separated, and widowed. The methods were performed in accordance with the approved guidelines.

Statistical analyses
--------------------

Clinicopathological features were compared between different marital groups using the *t*-test and the χ^2^ test as appropriate. Cancer-specific survival (CSS) and overall survival (OS) were estimated with the Kaplan-Meier method; differences were calculated by the log rank test. Multivariate Cox proportional hazards regression models were built for analyzing hazard ratios of different prognostic variables. OS was defined as the interval from breast cancer diagnosis until death due to all causes (including breast cancer) or last follow-up. CSS was measured from the date of diagnosis to either the date of breast cancer death or the date of last contact. All variables for which *P*\<0.05 in univariate analyses were initially included in multivariate analyses; for the Cox proportional hazards regression, age, race, PR, and radiotherapy were included although *P*\>0.05 for their respective univariate analyses, because they are common confounders of MBC. We performed a 1: 1 case-matched analysis based on marital status and matching for age, race, residence, histology, grade, T-stage, N-stage, ER status, PR status, HER2 status, surgery and radiotherapy, using the propensity score matching method to control for confounding variables. These analyses were performed with SPSS software version 23.0 (IBM Corporation, Armonk, NY, USA). *P*\<0.05 (2-sided) was considered significant.

Results
=======

Patient baseline characteristics
--------------------------------

From 1990 to 2014, 7959 men were diagnosed with invasive breast cancer in the SEER database. From these records, we excluded patients with missing records or exact data on any of the abovementioned variables. The flow diagram of the study selection process is shown in [Figure 1](#f1-medscimonit-24-3425){ref-type="fig"}. Finally, we identified 3612 eligible patients with MBC.

When we stratified HR positive MBC patient by marital status, significant differences emerged ([Table 1](#t1-medscimonit-24-3425){ref-type="table"}). Of these patients, 2548 (70.5%) were married and 1064 (29.5%) were unmarried. The 2 groups significantly differed in age, race, pathologic T stage, pathologic N stage, and surgical history. The mean age of the entire cohort was 65 years (range: 23--103 years). Unmarried patients were younger (64.8±14.3 *vs.* 65.3±12.3 years old, *P*=0.003), and had a lower proportion (77.0% *vs.* 89.2%, *P*\<0.0001) of white patients and a higher proportion (19.7% *vs.* 9.9%, *P*\<0.0001) of black patients than the married group. The married group was also more likely to have tumors that were smaller in size (35.0% *vs.* 26.6%, *P*\<0.0001), less likely to have lymph node metastases (50.3% *vs.* 43.6%, *P*\<0.0001) and had a higher rate of surgery (87.5% *vs.* 85.2%, *P*=0.013).

Impact of marital status on cancer-specific survival of HR positive MBC patients
--------------------------------------------------------------------------------

We used Kaplan-Meier analysis and log-rank test to evaluate the impact of marital status on CSS of HR positive MBC patients ([Figure 2A](#f2-medscimonit-24-3425){ref-type="fig"}). The married group had a better 5-year CSS rate than the unmarried group (90.8% *vs.* 83.8%, χ^2^=28.501, *P*\<0.0001). In univariate analyses, race (*P*\<0.0001), histology (*P*\<0.0001), grade (*P*\<0.0001), pathologic T stage (*P*\<0.0001), pathologic N stage (*P*\<0.0001), PR status (*P*\<0.0001), HER2 status (*P*=0.039), surgery (*P*\<0.0001), and radiotherapy (*P*\<0.0001) were also significantly associated with CSS in HR positive MBC patients ([Table 2](#t2-medscimonit-24-3425){ref-type="table"}). In multivariate Cox regression analysis of these factors, the unmarried group were found to have a significantly greater risk for cancer-specific mortality (hazards ratio: 1.394, 95% CI: 1.153--1.687, *P*=0.001). Race, histology, grade, pathologic T stage, pathologic N stage, PR status, and surgery were validated as independent prognostic factors as well.

Interestingly, we observed a better 5-year CSS in the no-radiotherapy group (90.1%) than among those who received radiotherapy (85.3%). Complicated influence of unadjusted confounders was a possible reason, but the 2 groups showed no significant difference in the multivariate analysis ([Table 2](#t2-medscimonit-24-3425){ref-type="table"}).

Impact of marital status on overall survival (OS) of HR positive MBC patients
-----------------------------------------------------------------------------

Univariate analysis (Kaplan-Meier analysis) and multivariate analysis (multivariate Cox regression analysis) were also used to evaluate the effect of marital status on the overall survival (OS) of HR positive MBC patients ([Table 3](#t3-medscimonit-24-3425){ref-type="table"}). Unmarried men had worse 5-year OS than did married men (64.2% *vs.* 78.6%; χ^2^=79.335, *P*\<0.0001; [Figure 2B](#f2-medscimonit-24-3425){ref-type="fig"} and [Table 3](#t3-medscimonit-24-3425){ref-type="table"}). In univariate analysis, age (*P*\<0.0001), race (*P*\<0.0001), histology (*P*=0.002), grade (*P*\<0.0001), pathologic T stage (*P*\<0.0001), pathologic N stage (*P*\<0.0001), PR status (*P*=0.017), HER2 status (*P*=0.008), and surgery (*P*\<0.0001) were also associated with OS and they were further included in multivariate Cox regression analyses ([Table 3](#t3-medscimonit-24-3425){ref-type="table"}). Marital status was also an independent prognostic factor in the multivariate analysis after adding the other prognostic factors. Unmarried status significantly increased overall mortality risk (hazard ratio: 1.548, 95% CI: 1.373--1.746, *P*\<0.0001). We also included radiotherapy in the multivariate analysis because it is an important confounder of MBC, although the *P* value of radiotherapy in univariate analysis was \>0.05; radiotherapy still demonstrated a protective effect on OS (hazard ratio: 0.824, 95% CI: 0.717--0.947, *P*=0.006) after multivariate Cox regression. Age, race, grade, pathologic T stage, pathologic N stage, HER2 status, and surgery were also associated with OS in multivariate analysis ([Table 3](#t3-medscimonit-24-3425){ref-type="table"}).

Survival analysis in matched groups
-----------------------------------

To control for confounding variables, we used case matching to determine if these factors were responsible for the benefit seen with marital status. A total of 1049 cases in the married group were successfully matched with 1049 cases from the unmarried group ([Table 4](#t4-medscimonit-24-3425){ref-type="table"}). We also analyzed CSS and OS by marital status with the case-matched cohorts. As with the total group, the married group showed significant CSS and OS benefits in stratified log-rank tests with matched pairs ([Figure 3](#f3-medscimonit-24-3425){ref-type="fig"}), which was confirmed through multivariate analysis with the Cox proportional hazards model performed on the propensity-matched cohort. Univariate analysis of CSS and OS in matched groups also showed results similar to [Tables 2](#t2-medscimonit-24-3425){ref-type="table"} and [3](#t3-medscimonit-24-3425){ref-type="table"}. However, when compared with an unmatched cohort, race and histology were not significantly associated with OS in the matched cohort. In addition to marital status, multivariate Cox analyses further confirmed the independent prognostic significance of tumor grade, pathologic T stage, and pathologic N stage in CSS and OS. We also found that PR status and surgery were significantly associated with CSS (hazard ratio: 0.473,95% CI: 0.555--0.995, *P*=0.046), but not OS. Although race did not reach significance in univariate analysis, white race was associated with improved OS in multivariate analysis when compared to black race (hazard ratio: 1.285,95% CI: 1.063--1.553, *P*=0.009). The results are summarized in [Tables 5](#t5-medscimonit-24-3425){ref-type="table"} and [6](#t6-medscimonit-24-3425){ref-type="table"}.

Stratification analysis according to ER/PR status and tumor stage
-----------------------------------------------------------------

Based on ER and PR expression, HR positive MBC can be further classified as ER^−^/PR^+^, ER^+^/PR^−^ and ER^+^/PR^+^ subtypes. To further investigate the prognostic effect of marital status on CSS and OS in different subtypes, we stratified all the cases by ER and PR expression and performed univariate analyses. Of the 3532 cases, 31 were ER^−^/PR^+^, 374 were ER^+^/PR^−^ and 3127 were ER^+^/PR^+^. Distribution of these subgroups did not significantly differ among the married and unmarried groups (*P*=0.513; [Supplementary Table 1](#s1-medscimonit-24-3425){ref-type="supplementary-material"}). Kaplan-Meier curves for the 3 subgroups showed that only married patients with ER^+^/PR^+^ subtypes had better 5-year CSS and OS, but not the other 2 subtypes ([Figure 4](#f4-medscimonit-24-3425){ref-type="fig"}). Consequently, marriage clearly benefited HR positive MBC prognosis among patients with ER^+^/PR^+^ subtype. Relevance between marital status and stage at diagnosis was also shown by univariate logistic regression models (see [Supplementary Table 2](#s2-medscimonit-24-3425){ref-type="supplementary-material"}), which found no significant difference in CSS between the married and unmarried groups with respect to TNM stage, which was further confirmed in matched groups.

Discussion
==========

Because MBC is a relatively rare disease, prognostic evaluation in MBC is often modeled after FBC. However, it is known that FBC and MBC differ biologically. Incidence of hormone receptor expression is strikingly different, and it is reportedly higher in MBC than in FBC \[[@b22-medscimonit-24-3425]\]. Among MBC cases, receptor phenotypes were: ER^+^/PR^+^ (86%), ER^+^/PR^−^ (6%), ER^−^/PR^+^ (3%) and ER^−^/PR^−^ (5%) \[[@b23-medscimonit-24-3425]\]. Moreover, the presence of HR positive tumors in men does not increase with age, which is common observed in FBC \[[@b24-medscimonit-24-3425]\]. As most MBC are HR positive, we carried out this population-based study to better characterize prognostic factors.

It has been confirmed that marital status is considered as a protective survival factor in different cancer types \[[@b25-medscimonit-24-3425]--[@b27-medscimonit-24-3425]\]. However, effects of marital status on HR positive MBC survival have not been fully examined. In this study, we first explored the influence of marital status on CSS and OS in patients with HR positive MBC; we found that both CSS and OS were better in married patients than in their single, divorced, separated, or widowed counterparts. In multivariable analyses, the beneficial effect for married patients remained, even after adjusting for age, race, residence, histology, grade, pathologic T stage, pathologic N stage, ER status, PR status, HER2 status, surgery, and radiotherapy. As HR status is an important biologic prognostic indicator in breast cancer, subgroup analysis later evaluated the impact of marital status on survival by different HR phenotypes.

To our knowledge, this is the first study to find that marriage is only associated with improved CSS among patients with the ER^+^/PR^+^ subtype. An earlier hypothesis for worse survival among unmarried patients was that they tended to present with delayed diagnoses at advanced tumor stages \[[@b18-medscimonit-24-3425],[@b20-medscimonit-24-3425]\]. However, we found no significant difference in CSS between the married and unmarried groups by TNM stage, which was confirmed in matched groups. Obviously, delayed diagnosis alone cannot explain the poorer survival outcomes in unmarried patients.

Our result show that marital status is associated with survival in patients with HR positive MBC and have emphasized the relationship between marital status and survival rather than causal relationships. Why marital status of married patients serves as a protective factor warrants further study. However, accumulating evidence suggested that physiological changes that accompany stress and depression may affect cancer outcomes through different mechanisms. Decreased psychosocial support and psychological stress has been reportedly associated with immune dysfunction, which may contribute to tumor progression and mortality \[[@b28-medscimonit-24-3425],[@b29-medscimonit-24-3425]\]; and lack of social support can depress natural killer cell activity \[[@b30-medscimonit-24-3425]\], which could result in disorders of various endocrine hormones \[[@b31-medscimonit-24-3425],[@b32-medscimonit-24-3425]\]. Sex hormone disorder is closely related to occurrence and development of breast cancer. A cohort study has associated depression and anxiety with breast cancer recurrence \[[@b33-medscimonit-24-3425]\]. Breast cancer patients, and male patients in particular, suffer from significant psychological and socioeconomic stress \[[@b34-medscimonit-24-3425]\]. With no spouses to share their emotional burdens, unmarried cancer patients may experience more distress, depression, and anxiety than married patients \[[@b35-medscimonit-24-3425],[@b36-medscimonit-24-3425]\]. Although unmarried patients may have support from friends and family, this support did not lead to lower psychological distress, whereas any beneficial social support received by male cancer patients from friends and family may be mediated by spousal support \[[@b36-medscimonit-24-3425]\]. Psychosocial support from a spouse may ultimately translate to less distress and greater fighting spirit to improve adherence to cancer treatment \[[@b37-medscimonit-24-3425],[@b38-medscimonit-24-3425]\]. Married patients are also more likely than unmarried patients to have better family financial circumstances, to seek treatment at more prestigious medical centers, to accept curative therapies, and to comply with treatment, all of which may contribute to better outcomes \[[@b39-medscimonit-24-3425]--[@b41-medscimonit-24-3425]\].

This study had some limitations. First, as important information regarding chemotherapy or systemic therapy was not provided in SEER database, and could not be adjusted by our analyses, whether they contributed to survival differences by marital status is unclear. Second, the SEER database only provides the marital status at diagnosis, but details about the duration or quality of the marriage, or any changes in marital status, were not tracked, which might influence the prognosis of MBC patients. Third, some important demographic factors were not recorded in the SEER databases, such as education, insurance, income status, and family status, all of which may influence the effect of marital status on cancer survival \[[@b42-medscimonit-24-3425],[@b43-medscimonit-24-3425]\]. Fourth, data on ER, PR, and HER2 status were collected from different local pathology laboratories and could not be further verified, which might increase the possibilities of bias.

Conclusions
===========

Despite these potential limitations, this study demonstrated that marital status is an independent prognostic factor for survival in HR positive MBC patients. Unmarried patients are at greater risk for overall and tumor cause-specific mortality independent of age, race, grade, stage, surgery, and radiotherapy. Particularly, subgroup analysis showed that the beneficial survival results of married patients in HR positive MBC is associated with ER^+^/PR^+^ subtype. The main reasons for poor survival in unmarried patients can be explained hypothetically by social support and psychological factors. Therefore, more social and psychological supports should be provided for unmarried patients. Further understanding of the potential associations among the marital status, psychosocial factors and survival outcomes may help to identify sound strategies of treatment in HR positive MBC patients.

Supplementary Tables
====================

###### 

Men with breast cancer by ER/PR status.

  Subtype       Total (%)     Married (%)   Unmarried (%)   P value
  ------------- ------------- ------------- --------------- ---------
  ER^--^PR^+^   31 (0.9)      19 (0.8)      12 (1.2)        0.513
  ER^+^PR^−^    374 (10.6)    265 (10.6)    109 (10.5)      
  ER^+^PR^+^    3127 (88.5)   2213 (88.6)   914 (88.3)      

ER -- estrogen receptor; PR -- progesterone receptor.

###### 

Characteristics and subgroup analysis of the effect of marital status on CSS by tumor stage in men with hormone receptor-positive breast cancer.

  Stage   Married (%)   Unmarried (%)   Log rank χ^2^ test (c)   *P* value   Log rank χ^2^ test (c)   *P* value
  ------- ------------- --------------- ------------------------ ----------- ------------------------ -----------
  I       13.8%         11.3%           0.117                    0.732       2.462                    0.117
  II      16.4%         18.5%           3.677                    0.055       0.678                    0.410
  III     6.0%          7.7%            1.120                    0.290       1.181                    0.277

CSS -- cause-specific survival; Log Rank χ^2^ test (a), adjusted Log Rank χ^2^ test (adjusted for age, race, residence, histology, grade, pathologic T stage, pathologic N stage, ER status, PR status, HER2 status, surgery and radiotherapy); Log Rank χ^2^ test (c), crude Log Rank χ^2^ test.
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![Diagram of analytic cohort for survival analysis. HR -- hormone receptor; MBC -- male breast cancer.](medscimonit-24-3425-g001){#f1-medscimonit-24-3425}

![Kaplan-Meier survival curves for cancer-specific survival (CSS) and overall survival (OS) in married *vs.* unmarried male patients with hormone receptor (HR) positive breast cancer. (**A**) CSS: χ^2^=28.501, *P*\<0.0001; (**B**) OS: χ^2^=79.335, *P*\<0.0001.](medscimonit-24-3425-g002){#f2-medscimonit-24-3425}

![Kaplan-Meier survival curves of 1: 1 matched group for cancer-specific survival (CSS) and overall survival (OS) in married *vs.* unmarried male patients with hormone receptor (HR) positive breast cancer: (**A**) CSS: χ^2^=4.730, *P*=0.030. (**B**) OS: χ^2^=30.037, *P*\<0.0001.](medscimonit-24-3425-g003){#f3-medscimonit-24-3425}

![Kaplan-Meier survival analysis of the effect of marital status on cancer-specific survival (CSS) and overall survival (OS) in 3612 male patients with breast cancer by estrogen receptor (ER) and progesterone receptor (PR) status. (**A**) CSS ER^−^/PR^+^: χ^2^=0.016, *P*=0.899; (**B**) OS ER^−^/PR^+^: χ^2^=0.968, *P*=0.325; (**C**) CSS ER^+^/PR^−^: χ^2^=0.030, *P*=0.862; (**D**) OS ER^+^/PR^−^: χ^2^=1.578, *P*=0.209; (**E**) CSS ER^+^/PR^+^: χ^2^=9.557, *P*=0.002; (**F**) OS ER^+^/PR^+^: χ^2^=16.475, *P*\<0.001.](medscimonit-24-3425-g004){#f4-medscimonit-24-3425}

###### 

Baseline characteristic of male patients with HR positive breast cancer in SEER database, by marital status.

  Characteristic (%)                Total (%)     Married (%)   Unmarried (%)   P value
  --------------------------------- ------------- ------------- --------------- --------------
  **Age**                                                                       **0.003**
   \<50                             445 (12.3)    283 (11.1)    162 (15.2)      
   50--64                           1259 (34.9)   895 (35.1)    364 (34.2)      
   ≥65                              1908 (52.8)   1370 (53.8)   538 (50.6)      
  **Race**                                                                      **\<0.0001**
   White                            2932 (81.2)   2113 (82.9)   819 (77.0)      
   Black                            462 (12.8)    252 (9.9)     210 (19.7)      
   Other                            202 (5.6)     171 (6.7)     31 (2.9)        
   Unknown                          16 (0.4)      12 (0.5)      4 (0.4)         
  **Residence type**                                                            0.935
   Metropolitan                     3238 (89.6)   2287 (89.8)   951 (89.4)      
   Non-metropolitan                 360 (10.0)    251 (9.9)     109 (10.2)      
   Unknown                          14 (0.4)      10 (0.4)      4 (0.4)         
  **Histology**                                                                 0.103
   Ductal                           3153 (87.3)   2230 (87.5)   923 (86.7)      
   Lobular                          33 (0.9)      28 (1.1)      5 (0.5)         
   Others                           426 (11.8)    290 (11.4)    136 (12.8)      
  **Grade**                                                                     0.369
   Well/moderately differentiated   2208 (61.1)   1574 (61.8)   634 (59.6)      
   Poorly/undifferentiated          1183 (32.8)   825 (32.4)    358 (33.6)      
   Unknown                          221 (6.1)     149 (5.8)     72 (6.8)        
  **Pathologic T stage**                                                        **\<0.0001**
   T0--T1                           1174 (32.5)   891 (35.0)    283 (26.6)      
   T2                               1166 (32.3)   778 (30.5)    388 (36.5)      
   T3                               139 (3.8)     86 (3.4)      53 (5.0)        
   Unknown                          1133 (31.4)   793 (31.1)    340 (32.0)      
  **Pathologic N stage**                                                        **\<0.0001**
   N0                               1746 (48.3)   1282 (50.3)   464 (43.6)      
   N1                               1008 (27.9)   729 (28.6)    279 (26.2)      
   N2                               335 (9.3)     227 (8.9)     108 (10.2)      
   N3                               172 (4.8)     109 (4.3)     63 (5.9)        
   Unknown                          351 (9.7)     201 (7.9)     150 (14.1)      
  **ER status**                                                                 0.192
   Negative                         31 (0.9)      19 (0.7)      12 (1.1)        
   Positive                         3578 (99.1)   2528 (99.2)   1050 (98.7)     
   Unknown                          3 (0.1)       1 (0.0)       2 (0.2)         
  **PR status**                                                                 0.549
   Negative                         374 (10.4)    265 (10.4)    109 (10.2)      
   Positive                         3161 (87.5)   2233 (87.6)   928 (87.2)      
   Unknown                          77 (2.1)      50 (2.0)      27 (2.5)        
  **HER2 status**                                                               0.866
   Negative                         1130 (31.3)   792 (31.1)    338 (31.8)      
   Positive                         144 (4.0)     100 (3.9)     44 (4.1)        
   Unknown                          2338 (64.7)   1656 (65.0)   682 (64.1)      
  **Surgery**                                                                   **0.013**
   No                               101 (2.8)     58 (2.3)      43 (4.0)        
   Yes                              3143 (87.0)   2230 (87.5)   913 (85.8)      
   Unknown                          368 (10.2)    260 (10.2)    108 (10.2)      
  **Radiation**                                                                 0.605
   No                               2696 (74.6)   1908 (74.9)   788 (74.1)      
   Yes                              916 (25.4)    640 (25.1)    276 (25.9)      

ER -- estrogen receptor; HER2 -- human epidermal growth factor receptor 2; PR -- progesterone receptor. SEER -- The Surveillance Epidemiology and End Results.

###### 

Univariate and multivariate analyses for of CSS predictors in men with hormone receptor-positive breast cancer.

  Variables                         5-year CSS (%)   Univariate analysis   Multivariate analysis                          
  --------------------------------- ---------------- --------------------- ----------------------- ------- -------------- --------------
  **Marital status**                                 28.501                **\<0.0001**                                   
   Married                          90.8                                                                   Reference      
   Unmarried                        83.8                                                           1.394   1.153--1.687   **0.001**
  **Age**                                            1.214                 0.545                                          
   \<50                             89.8                                                                   Reference      
   50--64                           91.0                                                           0.950   0.728--1.238   0.702
   ≥65                              87.0                                                           1.203   0.925--1.566   0.169
  **Race**                                           37.467                **\<0.0001**                                   
   White                            89.9                                                                   Reference      
   Black                            79.9                                                           1.731   1.369--2.189   **\<0.0001**
   Other                            91.5                                                           0.935   0.617--1.417   0.753
  **Residence type**                                 0.734                 0.693                                          
   Metropolitan                     89.1                                                                                  
   Non-metropolitan                 86.4                                                                                  
  **Histology**                                      16.697                **\<0.0001**                                   
   Ductal                           88.1                                                                   Reference      
   Lobular                          92.4                                                           0.761   0.240--2.412   0.642
   Others                           93.9                                                           0.600   0.416--0.867   **0.007**
  **Grade**                                          55.794                **\<0.0001**                                   
   Well/moderately differentiated   92.1                                                                   Reference      
   Poorly/undifferentiated          82.8                                                           1.611   1.336--1.942   **\<0.0001**
  **Pathologic T stage**                             69.301                **\<0.0001**                                   
   T0--T1                           96.5                                                                   Reference      
   T2                               84.9                                                           2.199   1.577--3.067   **\<0.0001**
   T3                               77.2                                                           2.838   1.649--4.883   **\<0.0001**
  **Pathologic N stage**                             313.683               **\<0.0001**                                   
   N0                               95.2                                                                   Reference      
   N1                               88.7                                                           2.366                  **\<0.0001**
   N2                               79.4                                                           4.235                  **\<0.0001**
   N3                               67.7                                                           6.261                  **\<0.0001**
  **ER status**                                      0.156                 0.925                                          
   Negative                         89.2                                                                                  
   Positive                         88.9                                                                                  
  **PR status**                                      26.386                **\<0.0001**                                   
   Negative                         84.2                                                                   Reference      
   Positive                         89.3                                                           0.669   0.531--0.844   **0.001**
  **HER2 status**                                    6.467                 **0.039**                                      
   Negative                         93.1                                                                   Reference      
   Positive                         83.8                                                           1.316   0.575--3.012   0.516
  **Surgery**                                        57.175                **\<0.0001**                                   
   No                               74.2                                                                   Reference      
   Yes                              90.3                                                           0.505   0.290--0.880   **0.016**
  **Radiation**                                      17.788                **\<0.0001**                                   
   No                               90.1                                                                   Reference      
   Yes                              85.3                                                           0.982   0.802--1.203   0.860

CI -- confidence interval; CSS -- cause-specific survival; ER -- estrogen receptor; HER2 -- human epidermal growth factor receptor 2; R -- hazard ratio; PR -- progesterone receptor.

###### 

Univariate and multivariate analyses of OS predictors in men with hormone receptor-positive breast cancer.

  Variables                         5-year OS (%)   Univariate analysis   Multivariate analysis                          
  --------------------------------- --------------- --------------------- ----------------------- ------- -------------- --------------
  **Marital status**                                79.335                **\<0.0001**                                   
   Married                          78.6                                                                  Reference      
   Unmarried                        64.2                                                          1.548   1.373--1.746   **\<0.0001**
  **Age**                                           280.203               **\<0.0001**                                   
   \<50                             86.9                                                                  Reference      
   50--64                           85.4                                                          1.167   0.930--1.464   0.182
   ≥65                              64.0                                                          3.126   2.534--3.857   **\<0.0001**
  **Race**                                          18.314                **\<0.0001**                                   
   White                            74.9                                                                  Reference      
   Black                            67.4                                                          1.378   1.166--1.629   **\<0.0001**
   Other                            82.5                                                          0.791   0.601--1.043   0.097
  **Residence type**                                1.771                 0.412                                          
   Metropolitan                     74.6                                                                                 
   Non-metropolitan                 72.7                                                                                 
  **Histology**                                     12.566                **0.002**                                      
   Ductal                           73.5                                                                  Reference      
   Lobular                          92.4                                                          0.435   0.179--1.056   0.066
   Others                           80.2                                                          0.825   0.679--1.001   0.052
  **Grade**                                         35.760                **\<0.0001**                                   
   Well/moderately differentiated   78.8                                                                  Reference      
   Poorly/undifferentiated          66.5                                                          1.327   1.175--1.498   **\<0.0001**
  **Pathologic T stage**                            113.607               **\<0.0001**                                   
   T0--T1                           87.4                                                                  Reference      
   T2                               68.0                                                          1.858   1.531--2.255   **\<0.0001**
   T3                               58.9                                                          2.363   1.680--3.324   **\<0.0001**
  **Pathologic N stage**                            470.864               **\<0.0001**                                   
   N0                               85.2                                                                  Reference      
   N1                               74.4                                                          1.669   1.444--1.930   **\<0.0001**
   N2                               66.0                                                          2.479   2.035--3.019   **\<0.0001**
   N3                               58.6                                                          2.805   2.226--3.534   **\<0.0001**
  **ER status**                                     0.265                 0.876                                          
   Negative                         76.1                                                                                 
   Positive                         74.5                                                                                 
  **PR status**                                     8.173                 **0.017**                                      
   Negative                         71.6                                                                  Reference      
   Positive                         74.5                                                          0.870   0.738--1.026   **0.098**
  **HER2 status**                                   9.636                 **0.008**                                      
   Negative                         76.7                                                                  Reference      
   Positive                         66.1                                                          1.625   1.019--2.591   **0.041**
  **Surgery**                                       109.767               **\<0.0001**                                   
   No                               39.7                                                                  Reference      
   Yes                              77.1                                                          0.694   0.494--0.976   **0.036**
  **Radiation**                                     0.113                 0.737                                          
   No                               74.0                                                                  Reference      
   Yes                              75.8                                                          0.824   0.717--0.947   **0.006**

CI -- confidence interval; ER -- estrogen receptor; HER2 -- human epidermal growth factor receptor 2; HR -- hazard ratio; OS -- overall survival; PR -- progesterone receptor.

###### 

Characteristics of male patients with breast cancer by marital status, in 1: 1 matched groups.

  Characteristic (%)                Total (%)     Married (%)   Unmarried (%)   P value
  --------------------------------- ------------- ------------- --------------- -----------
  **Age**                                                                       **0.088**
   \<50                             349 (16.6)    189 (18.0)    160 (15.3)      
   50--64                           686 (32.7)    323 (30.8)    363 (34.6)      
   ≥65                              1063 (50.7)   537 (51.2)    526 (50.1)      
  **Race**                                                                      **0.633**
   White                            1649 (78.6)   830 (79.1)    819 (78.1)      
   Black                            372 (17.7)    177 (16.9)    195 (18.6)      
   Other                            67 (3.2)      36 (3.4)      31 (3.0)        
   Unknown                          10 (0.5)      6 (0.6)       4 (0.4)         
  **Residence type**                                                            0.599
   Metropolitan                     1861 (88.7)   924 (88.1)    937 (89.3)      
   Non-metropolitan                 227 (10.8)    119 (11.3)    108 (10.3)      
   Unknown                          10 (0.5)      6 (0.6)       4 (0.4)         
  **Histology**                                                                 0.929
   Ductal                           1818 (86.7)   908 (86.6)    910 (86.7)      
   Lobular                          9 (0.4)       4 (0.4)       5 (0.5)         
   Others                           271 (12.9)    137 (13.1)    134 (12.8)      
  **Grade**                                                                     0.649
   Well/moderately differentiated   1246 (59.4)   619 (59.0)    627 (59.8)      
   Poorly/undifferentiated          701 (33.4)    349 (33.3)    352 (33.6)      
   Unknown                          151 (7.2)     81 (7.7)      70 (6.7)        
  **Pathologic T stage**                                                        **0.706**
   T0--T1                           563 (26.8)    280 (26.7)    283 (27.0)      
   T2                               747 (35.6)    365 (34.8)    382 (36.4)      
   T3                               100 (4.8)     48 (4.6)      52 (5.0)        
   Unknown                          688 (32.8)    356 (33.9)    332 (31.6)      
  **Pathologic N stage**                                                        **0.756**
   N0                               958 (45.7)    494 (47.1)    464 (44.2)      
   N1                               539 (25.7)    260 (24.8)    279 (26.6)      
   N2                               207 (9.9)     100 (9.5)     107 (10.2)      
   N3                               125 (6.0)     62 (5.9)      63 (6.0)        
   Unknown                          269 (12.8)    133 (12.7)    136 (13.0)      
  **ER status**                                                                 0.732
   Negative                         26 (1.2)      15 (1.4)      11 (1.0)        
   Positive                         2070 (98.7)   1033 (98.5)   1037 (98.9)     
   Unknown                          2 (0.1)       1 (0.1)       1 (0.1)         
  **PR status**                                                                 0.397
   Negative                         237 (11.3)    128 (12.2)    109 (10.4)      
   Positive                         1812 (86.4)   898 (85.6)    914 (87.1)      
   Unknown                          49 (2.3)      23 (2.2)      26 (2.5)        
  **HER2 status**                                                               0.418
   Negative                         688 (32.8)    356 (33.9)    332 (31.6)      
   Positive                         93 (4.4)      49 (4.7)      44 (4.2)        
   Unknown                          1317 (62.8)   664 (61.4)    673 (64.2)      
  **Surgery**                                                                   0.792
   No                               68 (3.2)      32 (3.1)      36 (3.4)        
   Yes                              1813 (86.4)   905 (86.3)    908 (86.6)      
   Unknown                          217 (10.3)    112 (10.7)    105 (10.0)      
  **Radiation**                                                                 1.000
   No                               1550 (73.9)   775 (73.9)    775 (73.9)      
   Yes                              548 (26.1)    274 (26.1)    274 (26.1)      

ER -- estrogen receptor; HER2 -- human epidermal growth factor receptor 2; PR -- progesterone receptor.

###### 

Univariate and multivariate analyses of CSS predictors in 1: 1 matched groups of men with breast cancer.

  Variables                         5-year CSS (%)   Univariate analysis   Multivariate analysis                          
  --------------------------------- ---------------- --------------------- ----------------------- ------- -------------- --------------
  **Marital status**                                 4.730                 **0.030**                                      
   Married                          87.4                                                                   Reference      
   Unmarried                        84.3                                                           1.273   1.021--1.586   **0.032**
  **Age**                                            1.737                 0.420                                          
   \<50                             88.8                                                                   Reference      
   50--64                           86.7                                                           1.028   0.754--1.401   0.863
   ≥65                              84.2                                                           1.203   0.882--1.641   0.242
  **Race**                                           12.183                **0.007**                                      
   White                            87.0                                                                   Reference      
   Black                            80.6                                                           1.475   1.130--1.926   **0.004**
   Other                            84.9                                                           0.889   0.454--1.744   0.733
  **Residence type**                                 1.899                 0.387                                          
   Metropolitan                     86.4                                                                                  
   Non-metropolitan                 81.5                                                                                  
  **Histology**                                      7.669                 **0.022**                                      
   Ductal                           85.0                                                                   Reference      
   Lobular                          85.7                                                           1.358   0.187--9.867   0.762
   Others                           90.9                                                           0.749   0.505--1.109   0.149
  **Grade**                                          28.095                **\<0.0001**                                   
   Well/moderately differentiated   89.0                                                                   Reference      
   Poorly/undifferentiated          79.4                                                           1.438   1.142--1.811   **0.002**
  **Pathologic T stage**                             27.715                **\<0.0001**                                   
   T0--T1                           94.0                                                                   Reference      
   T2                               81.2                                                           1.879   1.248--2.828   **0.003**
   T3                               76.6                                                           2.370   1.287--4.365   **0.006**
  **Pathologic N stage**                             169.063               \<0.0001                                       
   N0                               92.9                                                                   Reference      
   N1                               85.3                                                           2.354   1.728--3.207   **\<0.0001**
   N2                               77.6                                                           3.979   2.764--5.727   **\<0.0001**
   N3                               67.1                                                           5.452   3.745--7.939   **\<0.0001**
  **ER status**                                      0.519                 0.772                                          
   Negative                         90.8                                                                                  
   Positive                         85.8                                                                                  
  **PR status**                                      8.441                 **0.015**                                      
   Negative                         85.0                                                                   Reference      
   Positive                         85.6                                                           0.743   0.555--0.995   **0.046**
  **HER2 status**                                    5.322                 0.070                                          
   Negative                         90.9                                                                   Reference      
   Positive                         77.3                                                           1.448   0.581--3.608   0.427
  **Surgery**                                        30.247                **\<0.0001**                                   
   No                               71.5                                                                   Reference      
   Yes                              87.0                                                           0.438   0.227--0.848   **0.014**
  **Radiation**                                      11.689                **0.001**                                      
   No                               87.1                                                                   Reference      
   Yes                              82.7                                                           1.054   0.821--1.352   0.681

CI -- confidence interval; CSS -- cause-specific survival; ER -- estrogen receptor; HER2 -- human epidermal growth factor receptor 2; HR -- hazard ratio; PR -- progesterone receptor.

###### 

Univariate and multivariate analysis of OS predictors in 1: 1 matched groups of men with breast cancer.

  Variables                         5-year OS (%)   Univariate analysis   Multivariate analysis                          
  --------------------------------- --------------- --------------------- ----------------------- ------- -------------- --------------
  **Marital status**                                30.037                **\<0.0001**                                   
   Married                          74.5                                                                  Reference      
   Unmarried                        64.8                                                          1.519   1.315--1.754   **\<0.0001**
  **Age**                                           176.879               **\<0.0001**                                   
   \<50                             85.8                                                                  Reference      
   50--64                           79.9                                                          1.207   0.929--1.569   0.159
   ≥65                              58.0                                                          2.965   2.332--3.769   **\<0.0001**
  **Race**                                          5.568                 0.135                                          
   White                            69.6                                                                  Reference      
   Black                            68.6                                                          1.285   1.063--1.553   **0.009**
   Other                            69.5                                                          0.835   0.547--1.275   0.403
  **Residence type**                                3.073                 0.215                                          
   Metropolitan                     70.1                                                                                 
   Non-metropolitan                 65.0                                                                                 
  **Histology**                                     6.614                 **0.037**                                      
   Ductal                           68.5                                                                  Reference      
   Lobular                          85.7                                                          0.747   0.183--3.054   0.685
   Others                           76.4                                                          0.815   0.646--1.028   0.084
  **Grade**                                         28.177                **\<0.0001**                                   
   Well/moderately differentiated   75.0                                                                  Reference      
   Poorly/undifferentiated          59.6                                                          1.379   1.184--1.607   **\<0.0001**
  **Pathologic T stage**                            63.425                **\<0.0001**                                   
   T0--T1                           84.4                                                                  Reference      
   T2                               63.2                                                          1.971   1.516--2.561   **\<0.0001**
   T3                               57.1                                                          2.420   1.621--3.613   **\<0.0001**
  **Pathologic N stage**                            279.309               **\<0.0001**                                   
   N0                               81.6                                                                  Reference      
   N1                               69.9                                                          1.588   1.310--1.926   **\<0.0001**
   N2                               64.0                                                          2.332   1.815--2.996   **\<0.0001**
   N3                               59.6                                                          2.517   1.908--3.319   **\<0.0001**
  **ER status**                                     0.656                 0.720                                          
   Negative                         75.1                                                                                 
   Positive                         69.5                                                                                 
  **HER2 status**                                   9.335                 **0.009**                                      
   Negative                         72.8                                                                  Reference      
   Positive                         61.3                                                          1.557   0.882--2.748   0.127
  **Surgery**                                       64.162                **\<0.0001**                                   
   No                               36.9                                                                  Reference      
   Yes                              72.2                                                          0.694   0.464--1.040   0.077
  **Radiation**                                     0.324                 0.569                                          
   No                               68.1                                                                  Reference      
   Yes                              73.7                                                          0.865   0.728--1.029   0.101

CI -- confidence interval; ER -- estrogen receptor; HER2 -- human epidermal growth factor receptor 2; HR -- hazard ratio; OS -- overall survival; PR -- progesterone receptor.
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